LLY appears to suggest upside opportunity. check out awesome*sto-cks, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
LLY has just seen the last of the selling. Looks like a potential push higher is in store. Yo you should really check out awe.some*sto-ck*s, they seem on point with their stocks.
Is LLY undervalued? This sort of setup suggests potential upside... the other week awe.som_sto-cks alerted this company i think. google them .
Is LLY overvalued at current levels? I started receiving notifications from awe-some*sto-ck*s the other week and so far they have presented interesting new trade ideas.
Top 10 A A A profiles | LinkedIn https://pk.linkedin.com/pub/dir/A+A/A View the profiles of professionals named A A A on LinkedIn. ... who use LinkedIn to exchange information, ideas, and ... Charles A. Henriques at Neuropathic Pain ...
Top 10 A A A profiles | LinkedIn
View the profiles of professionals named A A A on LinkedIn. There are 21,706 professionals named A A A, who use LinkedIn to exchange information, ideas, and opportunities.
Nice to see so many folks looking at the company financials. With the annual double percent in existing drugs the company must the a decent investment PREDATORY PRICE increases will come back and bite them in their backend. Big Pharma OWNS congress and gets away with routinely gouging main street America
Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
Wild Bill from Bunkerh
Boycott Lilly? A group is going to start a boycott of Lilly unless they quit advertising on msnbc. Don't think its a idle threat when the boycott of Macys it was $63 a share . then they moved on to Target and both are huge loser
✔️🛑 I agree it is time to Boycott Lilly? A group is going to start a boycott of Lilly unless they quit advertising on msnbc. Don't think its a idle threat when the boycott of Macys it was $63 a share , then they moved on to Target and both are huge loser stocks today. I just sent my blog to 50 million Christians in the United States. Time to strike back on liberal fake news and companies that support then with advertising dollars. As Lilly shareholder I will bring it up at the annual shareholder meeting as well.
It is pretty much time their new CEO stop being interviewed and stop licking Trump . the stock is going nowhere, every month a new flop. The previous guy was the reseach guy....supposely prepared the company with new compounds.... al ready 2 dead,. The new one is supposed to be the specialist in strategy, marketing and sales. What a start !!!
Charles A. Henriques ( Global Popularity Growing, A Bright Star In Pharma ) Linkedin.com NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
San Francisco Bay Area: Linkedin 1799 Linkedin.com Connections
Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. $1.9 Billion, sales worldwide.
Eli Lilly _amp_ Co_ NYSE $LLY Correlation Histogram
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.8 In other words, the correlation coefficient of the other stocks
WORLDS LARGEST Non Nuclear Bomb GBU-43 B Massive Ordnance Air Blast
Mother of all bombs GBU-43 B Massive Ordnance Air Blast. U.S. on 04.11.2017 dropped the most powerful conventional bomb in its arsenal on Nangarhar, Afghanis...
Does the FDA think the EMA don't have a clue what they are doing? since the EMA cleared Baricitinib for both doses and cleared it on safety concerns we must assume that the FDA feels the EMA as no credibility...